CANCER JOURNAL

Scope & Guideline

Uncovering the Mysteries of Cancer for Better Care.

Introduction

Welcome to the CANCER JOURNAL information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of CANCER JOURNAL, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1528-9117
PublisherLIPPINCOTT WILLIAMS & WILKINS
Support Open AccessNo
CountryUnited States
TypeJournal
Converge1996, 1998, from 2000 to 2024
AbbreviationCANCER J / Cancer J.
Frequency6 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressTWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103

Aims and Scopes

The Cancer Journal aims to provide a comprehensive platform for the dissemination of research findings and clinical advancements in the field of hematological malignancies. It encompasses a broad spectrum of topics related to blood cancers, focusing on the latest developments in diagnosis, treatment, and patient management.
  1. Hematological Malignancies:
    The journal primarily focuses on various types of blood cancers, including but not limited to acute myeloid leukemia (AML), multiple myeloma, and lymphomas, providing insights into their biology, clinical features, and treatment strategies.
  2. Genomic and Molecular Insights:
    A significant emphasis is placed on the genomic and molecular underpinnings of hematological malignancies, exploring mutations, rearrangements, and genetic predispositions that impact disease prognosis and treatment response.
  3. Clinical Trials and Therapeutics:
    The journal features studies on clinical trials, evaluating new therapeutic agents and treatment regimens, including CAR-T cell therapies, bispecific antibodies, and combination therapies to enhance patient outcomes.
  4. Real-World Evidence and Patient Outcomes:
    Research examining real-world data, treatment patterns, and long-term outcomes in patients with hematological malignancies is a core area of focus, providing insights into the effectiveness of therapies in diverse populations.
  5. Disparities in Care:
    The journal addresses disparities in access to treatment and outcomes based on race, socioeconomic status, and other demographic factors, highlighting the need for equitable healthcare in oncology.
The Cancer Journal is at the forefront of emerging themes and trends in hematological malignancies, reflecting the dynamic nature of research and clinical practice. This section outlines the key areas gaining traction in recent publications.
  1. Immunotherapy and CAR-T Cell Therapies:
    There is a significant increase in research focusing on immunotherapeutic approaches, particularly CAR-T cell therapies, which are showing promise in treating various hematological malignancies, including relapsed/refractory cases.
  2. Multi-Omics Approaches:
    Emerging studies employing multi-omics techniques are gaining popularity, enabling a more comprehensive understanding of the molecular landscape of blood cancers, which can inform personalized treatment strategies.
  3. Minimal Residual Disease (MRD) Monitoring:
    The importance of MRD monitoring is increasingly recognized, with research focusing on its prognostic value and implications for treatment decisions, particularly in AML and multiple myeloma.
  4. Real-World Evidence and Patient-Centric Research:
    There is a growing trend towards utilizing real-world data to assess treatment efficacy, patient outcomes, and healthcare disparities, emphasizing the need for evidence that reflects everyday clinical practice.
  5. Genetic and Epigenetic Modifications:
    Research into the genetic and epigenetic alterations associated with hematological malignancies is on the rise, providing insights into disease mechanisms and potential therapeutic targets.

Declining or Waning

As the Cancer Journal evolves, certain themes that were once prominent may be experiencing a decline in frequency or relevance. This section identifies these waning scopes, reflecting shifts in research focus and priorities within the field.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in studies focusing solely on traditional chemotherapy regimens, as the field increasingly shifts towards targeted therapies and immunotherapies that offer improved efficacy and reduced toxicity.
  2. Single-Agent Studies:
    Research centered on single-agent therapies is becoming less common, with a growing trend towards combination therapies that leverage synergistic effects to enhance treatment outcomes.
  3. Basic Science Research:
    While foundational research remains important, there appears to be a reduction in publications emphasizing basic science without direct clinical implications, as the journal prioritizes translational and clinical studies that impact patient care.

Similar Journals

LEUKEMIA & LYMPHOMA

Transforming the landscape of cancer treatment and care.
Publisher: TAYLOR & FRANCIS LTDISSN: 1042-8194Frequency: 12 issues/year

LEUKEMIA & LYMPHOMA is a prestigious peer-reviewed journal published by Taylor & Francis Ltd, focusing on vital research in the fields of hematology, oncology, and cancer research. With an ISSN of 1042-8194 and an E-ISSN of 1029-2403, this journal is recognized for its high-quality and impactful contributions to understanding blood cancers, with a notable impact factor reflective of its influence. Since its inception in 1989, LEUKEMIA & LYMPHOMA has continuously provided a platform for researchers and professionals to disseminate their findings, fostering advancements in diagnostic, therapeutic, and clinical strategies related to leukemias and lymphomas. The journal ranks in the Q2 category for both Hematology and Oncology research categories as of 2023, underscoring its commitment to excellence. The journal is based in the United Kingdom and serves a global audience, making it an essential resource for those dedicated to improving outcomes for patients with hematological malignancies.

JTO Clinical and Research Reports

Innovating Solutions in Oncology and Pulmonary Health
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

JTO Clinical and Research Reports is an esteemed open-access journal published by Elsevier, dedicated to advancing knowledge in the fields of Oncology and Pulmonary and Respiratory Medicine. Since its inception in 2020, the journal has rapidly gained recognition, achieving a commendable Q1 ranking in both fields as of 2023, highlighting its significant contribution to high-quality research and clinical practice. With an inclusive global reach, JTO Clinical and Research Reports fosters collaboration by allowing unrestricted access to its content, ensuring that vital research findings can be disseminated widely among researchers, clinicians, and students alike. Located in the United States, and with its editorial base in the Netherlands, this journal not only embraces the mission of open science but also strives to publish impactful studies that address critical challenges in cancer treatment and respiratory health. Through its rigorous peer-review process and commitment to excellence, JTO Clinical and Research Reports aims to be at the forefront of scientific discourse and innovation in these dynamic areas of medicine.

Experimental Hematology & Oncology

Transforming Research into Breakthroughs in Hematology & Oncology
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Clinical Lymphoma Myeloma & Leukemia

Illuminating the Path in Hematologic Oncology
Publisher: CIG MEDIA GROUP, LPISSN: 2152-2650Frequency: 6 issues/year

Clinical Lymphoma Myeloma & Leukemia is a prestigious journal dedicated to the study and treatment of hematologic malignancies, offering a vital platform for researchers and healthcare professionals in the fields of oncology, hematology, and cancer research. Published by CIG MEDIA GROUP, LP, this journal has established itself as a crucial resource since its inception in 2010, with a continuous commitment to disseminating knowledge until at least 2024. With an impact factor that objectively reflects its influence, it is rated in Q3 quartiles in both Cancer Research and Hematology as well as in Oncology as of 2023. Researchers can access a wealth of articles and studies that explore various dimensions of lymphoma, myeloma, and leukemia, thus fostering an environment of collaboration and innovation. Although it currently does not offer full open access, its extensive archive and rigorous peer-review process ensure the publication of high-quality research, making it an essential resource for anyone dedicated to advancing the science and practice of treating blood cancers.

Cancer Research Communications

Bridging gaps in cancer knowledge and practice.
Publisher: AMER ASSOC CANCER RESEARCHISSN: Frequency: 1 issue/year

Cancer Research Communications is an esteemed journal published by the American Association for Cancer Research, a leading organization in the field of oncology. This journal aims to advance knowledge in cancer research through the dissemination of high-quality, peer-reviewed articles that cover a wide range of topics related to cancer biology, treatment modalities, and prevention strategies. As an open-access journal, Cancer Research Communications ensures that vital research findings are accessible to a global audience, promoting collaboration and innovation within the scientific community. The journal serves as a crucial platform for researchers, professionals, and students to share their insights and foster the exchange of effective cancer therapies and methodologies. With a commitment to excellence, it plays a significant role in shaping the future of cancer research and therapeutic development.

Clinical Genitourinary Cancer

Advancing knowledge in genitourinary oncology.
Publisher: CIG MEDIA GROUP, LPISSN: 1558-7673Frequency: 6 issues/year

Clinical Genitourinary Cancer, published by CIG MEDIA GROUP, LP, is a leading journal in the fields of Oncology and Urology, with an impressive impact reflected in its quartile rankings (Q2 in Oncology and Q1 in Urology for 2023) and strong Scopus rankings (22nd in Urology and 162nd in Oncology). The journal aims to innovate and inspire new research in genitourinary malignancies, providing a platform for the latest findings in diagnosis, treatment, and patient management. With its commitment to high-quality publications since its establishment in 2005, Clinical Genitourinary Cancer serves a crucial role in advancing the understanding of these complex conditions and enhancing clinical practices. Researchers, professionals, and students in the medical community are encouraged to engage with this essential resource, which facilitates open access to pioneering studies that drive the field forward.

LEUKEMIA RESEARCH

Pioneering research for innovative leukemia treatments.
Publisher: PERGAMON-ELSEVIER SCIENCE LTDISSN: 0145-2126Frequency: 12 issues/year

Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.

Blood Science

Elevating Knowledge in Hematology and Transfusion Medicine
Publisher: LIPPINCOTT WILLIAMS & WILKINSISSN: 2543-6368Frequency:

Blood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.

Oncology Research and Treatment

Advancing cancer care through innovative research.
Publisher: KARGERISSN: 2296-5270Frequency: 10 issues/year

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

World Journal of Clinical Oncology

Fostering Collaboration in the Fight Against Cancer
Publisher: BAISHIDENG PUBLISHING GROUP INCISSN: 2218-4333Frequency: 12 issues/year

World Journal of Clinical Oncology, published by BAISHIDENG PUBLISHING GROUP INC, stands as a vital resource in the realm of oncology, providing a dedicated platform for the dissemination of cutting-edge research and clinical advancements. With an ISSN of 2218-4333, this journal facilitates a comprehensive exploration of modern oncology challenges and breakthroughs, targeting researchers, healthcare professionals, and students alike. Although it operates under the traditional subscription model, the impactful nature of its content is reflected in its notable ranking of 60 out of 334 in the category of Medicine _ Oncology, placing it in the 82nd percentile among peer publications. Covering significant topics in clinical oncology from 2014 to 2018, the journal has been instrumental in addressing evolving oncology practices and patient care innovations. By publishing high-quality studies, it remains an essential tool for advancing knowledge and fostering collaboration within the global oncology community.